A5074482150- Antibiotics Pharmacokinetics and Efficacy
- Antibiotic Resistance in Bacteria
- Cancer Treatment and Pharmacology
- Statistical Methods in Clinical Trials
- Pneumonia and Respiratory Infections
- Cancer Genomics and Diagnostics
- Neutropenia and Cancer Infections
- Cancer therapeutics and mechanisms
- Pharmacogenetics and Drug Metabolism
- Drug Transport and Resistance Mechanisms
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Treatments and Studies
- Bacteriophages and microbial interactions
- Polyomavirus and related diseases
- Mathematical Biology Tumor Growth
- Gastric Cancer Management and Outcomes
- Antibiotic Use and Resistance
- Bacterial Identification and Susceptibility Testing
- Lung Cancer Treatments and Mutations
- Chronic Myeloid Leukemia Treatments
- Pharmaceutical studies and practices
- Pharmaceutical and Antibiotic Environmental Impacts
- Poisoning and overdose treatments
- Lung Cancer Research Studies
- Immune Response and Inflammation
Uppsala University
2016-2025
University of Cape Town
2020
Obafemi Awolowo University
2020
Leiden University
2016-2017
Centre for Human Drug Research
2016
University of Otago
2016
Center for Environmental Health
2016
University of Illinois Urbana-Champaign
2016
University of Minnesota
2016
Erasmus MC Cancer Institute
2004-2013
PURPOSE: To develop a semimechanistic pharmacokinetic-pharmacodynamic model describing chemotherapy-induced myelosuppression through drug-specific parameters and system-related parameters, which are common to all drugs. PATIENTS AND METHODS: Patient leukocyte neutrophil data after administration of docetaxel, paclitaxel, etoposide were used the model, was also applied from 2′-deoxy-2′-methylidenecytidine (DMDC), irinotecan (CPT-11), vinflunine administrations. The consisted proliferating...
ABSTRACT Colistin is used to treat infections caused by multidrug-resistant gram-negative bacteria (MDR-GNB). It administered intravenously in the form of colistin methanesulfonate (CMS), which hydrolyzed vivo active drug. However, pharmacokinetic data are limited. The aim present study was characterize pharmacokinetics CMS and a population critically ill patients. Patients receiving for treatment MDR-GNB were enrolled study; however, patients renal replacement therapy excluded. at dose 3...
A pharmacokinetic-pharmacodynamic (PKPD) model that characterizes the full time course of in vitro time-kill curve experiments antibacterial drugs was here evaluated its capacity to predict previously determined PK/PD indices. Six (benzylpenicillin, cefuroxime, erythromycin, gentamicin, moxifloxacin, and vancomycin), representing a broad selection mechanisms action PK PD characteristics, were investigated. For each drug, dose fractionation study simulated, using wide range total daily doses...
ABSTRACT A previous pharmacokinetic study on dosing of colistin methanesulfonate (CMS) at 240 mg (3 million units [MU]) every 8 h indicated that has a long half-life, resulting in insufficient concentrations for the first 12 to 48 after initiation treatment. loading dose would therefore be beneficial. The aim this was evaluate CMS and pharmacokinetics following 480-mg (6-MU) critically ill patients explore bacterial kill use different regimens obtained by predictions from...
Interindividual pharmacokinetic variability of the anticancer agent irinotecan is high. Life-threatening diarrhea observed in up to 25% patients receiving and has been related with pharmacokinetics UGT1A1 genotype status. Here, we explore association ABCC2 (MRP2) polymorphisms haplotypes disposition diarrhea. A cohort 167 Caucasian cancer who were previously assessed for (90-min infusion given every 21 days), toxicity, UGT1A1*28 genotyped using Pyrosequencing. Fifteen identified studied...
ABSTRACT To further optimize the voriconazole dosing in pediatric population, a population pharmacokinetic analysis was conducted on pooled data from 112 immunocompromised children (2 to <12 years), 26 adolescents (12 <17 and 35 healthy adults. Different maintenance doses (i.e., 3, 4, 6, 7, 8 mg/kg of body weight intravenously [i.v.] every 12 h [q12h]; 4 mg/kg, 6 200 mg orally q12h) were evaluated these children. The adult regimens (6 i.v. q12h day 1, followed by q12h, 300 adolescents....
Abstract Background We evaluated the association between mortality and colistin resistance in Acinetobacter baumannii infections interaction with antibiotic therapy. Methods This is a secondary analysis of randomized controlled trial patients carbapenem-resistant gram-negative bacterial treated or colistin-meropenem combination. infection caused by A. (CRAB) identified as susceptible (CoS) at time treatment compared which isolate was confirmed CoS those whose isolates were retrospectively...
Imatinib minimal (trough) plasma concentrations after one month of treatment have shown a significant association with clinical benefit in patients gastrointestinal stromal tumors (GIST). Considering that retrospective pharmacokinetic analysis has also suggested imatinib clearance increases over time soft tissue sarcoma and GIST, the primary aim this study was to assess systemic exposure at multiple points long-term prospective population study. As is mainly metabolized liver, our secondary...
Colistin has been revived, in the era of extensively drug-resistant (XDR) Gram-negative infections, as last-resort treatment critically ill patients. Recent studies focusing on optimal dosing strategy colistin have demonstrated necessity a loading dose at initiation (D. Plachouras, M. Karvanen, L. E. Friberg, Papadomichelakis, A. Antoniadou, I. Tsangaris, Karaiskos, G. Poulakou, F. Kontopidou, Armaganidis, O. Cars, and H. Giamarellou, Antimicrob Agents Chemother 53:3430-3436, 2009,...
Several constituents of cigarette smoke are known to interact with drug metabolizing enzymes and potentially affect treatment outcome substrate drugs. The purpose this study was determine the effects smoking on pharmacokinetics adverse irinotecan.A total 190 patients (49 smokers, 141 nonsmokers) treated irinotecan (90-minute intravenous administration a 3-week schedule) were evaluated for pharmacokinetics. Complete toxicity data available in subset 134 receiving 350 mg/m2 or 600 mg...
Background: Irinotecan is a topoisomerase I inhibitor that has been approved for use as first- and second-line treatment colorectal cancer. The response to irinotecan variable, possibly because of interindividual variation in the expression enzymes metabolize irinotecan, including cytochrome P450 3A4 (CYP3A4) uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). We prospectively explored relationships between CYP3A phenotype, assessed by erythromycin metabolism midazolam clearance, its...
The relationships between metals like lead, cadmium, and mercury other factors that quantitatively qualitatively modify their metabolism toxicity are surveyed. Interactions examined by scientists from a variety of fields covering biochemistry, ecology, epidemiology, nutrition, occupational health, toxicology. Evidence interactions among arsenic, mercury, these elements selenium, calcium, copper, zinc, iron is considered. There ample evidence animal experiments many occur. enhancing influence...
Abstract Purpose: Paclitaxel is used for the treatment of several solid tumors and displays a high interindividual variation in exposure toxicity. Neurotoxicity one most prominent side effects paclitaxel. This study explores potential predictive pharmacokinetic pharmacogenetic determinants onset severity neurotoxicity. Experimental Design: In an exploratory cohort patients (n = 261) treated with paclitaxel, neurotoxicity incidence, severity, parameters variants were determined. plasma...